Supplementary Figure S7 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus

Supplementary Figure S7. Kinase profiling of 6K465 and alisertib. Analyzing kinase profiles of 6K465 (tested at 0.1 uM) and alisertib (tested at 1.0 uM) reveals notable distinctions. The kinase profiling data for alisertib was sourced from the publication by Manfredi et al. (47); top 50 hit kinases for each of the compound are presented. Percent (%) inhibition values represent the mean from two replicate experiments, with color-coding indicating the efficacy of inhibition. NA, not available.